NCT07010497
A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
Phase: Phase 2
Role: Collaborator
Start: Nov 14, 2025
Completion: Mar 31, 2029